Immune checkpoint inhibitor (ICI) therapeutics is a growing area of cancer immunotherapy that serves to induce anti-tumor immune responses via a blockade of immune checkpoint proteins, namely, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) [1]. Here, PDCD1 is linked to neoplasm.